Although not yet investigated in detail, such a BCR–VLA-4 interplay may be relevant in CLL particularly in the light of the central role played by the BCR pathway in this disease (Burger and Chiorazzi, 2013; Wiestner, 2015), as witnessed by the emerging remarkable clinical activities of several inhibitors that interfere with the action of key BCR-related intracellular enzymes (Woyach et al., 2012; Wiestner, 2014). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.